APOTEX

Flyers > Features and Favourites news papers Pharmacies

150 SIGNET DR VTORONTO ONT M9L 1T9

Founded in 1974 by Dr. Barry Sherman, we’re a proudly Canadian, global pharmaceutical company that produces high-quality, affordable medicines (both generic and innovative pharmaceuticals) for patients around the world.

From its humble origins of only two employees, we’ve grown to employ more than 11,000 people worldwide in manufacturing, R&D and commercial operations.

Through vertical integration, the Apotex Group of Companies is comprised of Apotex Generics, Apotex Active Pharmaceutical Ingredients, Apobiologix and ApoPharma (innovative products).

Our Global Footprint

We export to more than 115 countries and territories and operate in more than 45 countries, including a significant presence in the US, Mexico, and India where we continue to invest.

Our footprint includes an expanding network of Affiliates and Distributors, as well as joint ventures and strategic alliances.

Globally, we produce approximately 25 billion doses per year, which, in turn, are used to fill approximately 90 million prescriptions in Canada alone or one in five prescriptions.

Our Contribution to Sustainable Healthcare

In the past five years alone, we have helped to bring more than 20 prescription drugs to market before patent expiry, and in doing so, saved public and private payers more than $4 billion. In total, we have saved Canadians almost $19 billion by bringing products to market early.

Our Commitment To R&D

We are the single largest investor in research and development of any pharmaceutical company in Canada – brand or generic.

We have the largest labs in the Canadian pharmaceutical industry and more than 1100 active R&D projects representing more than 500 molecules in 50 countries.

In the past 10 years, we have invested $1 billion in research and development, with an additional $2 billion planned for the next 10 years.

News of Note—Apotex tries to kick-start murder probe with $10M reward

Apotex plant in India hit with a third warning letter in 4 years

Fingerprints, DNA not identified 10 months after Sherman murders: lawyer

Barry Sherman had a trainload of bitter enemies.

Sherman murder probe obtains seven more searc h warrants

Barry and Honey Sherman were murdered by multiple killers, private investigators believe: source

Homicide investigators take lead in Barry and Honey Sherman case

Apotex Canada - An Overview

Apotex founder barry sherman and wife found dead in toronto home

Barry and Honey Sherman remembered at funeral

BARRY SHERMAN: Who bumped off the Canadian billionaire and why?

Barry Sherman and Honey Sherman Murdered

Honey Sherman: 5 Fast Facts You Need to Know

Deaths of Honey and Barry ShermanCBC LINDA WARD

Pharma Billionaire and Wife with Ties to Trudeau found Dead in Home

The (((Barry Sherman))) and (((David Sassoon))) Pharmakeia Connection #436

Veteran cop leading Sherman probe has track record of high-profile death investigations

Det.-Sgt. Susan Gomes is the lead investigator now examining the suspicious deaths of billionaires Barry and Honey Sherman.

Barry Sherman was under investigation for breaking lobbying rules

Billionaire Barry Sherman filed a lawsuit to quash an investigation into a Liberal Party fundraiser he hosted that may have breached lobbying rules

Apotex focused on navigating past ‘terrible tragedy’ after death of founder Barry Sherman

None of Sherman's four children were interested in running the business

Launch of biosimilar filgrastim From Wikipedia

In 2013, Apotex began selling a biosimilar version of Amgen's Neulasta in Europe, a blockbuster drug used by cancer patients in chemotherapy as a way to boost white blood count. Apotex's version is known as Grastofil (filgrastim) and is licensed for sale in Europe by Stada Arzneimittel.^[23] In February 2015, the FDA accepted Apotex's application of its filing of Grastofil in the United States

Medical ethics and impacts of attempts to silence researchers

From Wikipedia

A critical review of Miriam Shuchman's 2005 book about Dr. Nancy Olivieri versus Apotex, summarizes how "Nancy Olivieri is famous for raising doubts about an experimental drug with which she was treating thalassemia patients.

Her principled stand and the resulting scandal led universities to offer researchers some protection against illegitimate drug company pressure.

Medical journals changed their publication rules. Research hospitals changed their policies. She became an international icon. Apotex, the drug company which tried to silence her, has attracted international opprobrium.

The company threatened to sue Olivieri if she publicly revealed her fears about the inadequacy of their drug, deferiprone. She sued them for libeling her; they sued her ($20 million) for libeling their drug."